Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination

International Journal of Infectious Diseases

Volumn 56, Issue , 2017, Pages 140-154

  Valentini, Davide ^a,b   Rao, Martin ^b   Rane, Lalit ^b   Rahman, Sayma ^b   Axelsson Robertson, Rebecca ^a,b   Heuchel, Rainer ^b   Löhr, Matthias ^b   Hoft, Daniel ^c   Brighenti, Susanna ^b   Zumla, Alimuddin ^d   Maeurer, Markus ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bacille Calmette Gu rin; Immuno editing; Immunoglobulin gamma; Peptide microarray

Indexed keywords

ANGIOPOIETIN; BCG VACCINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN G ANTIBODY; INOSITOL; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4 RECEPTOR; RIBONUCLEOPROTEIN; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VESICULAR MONOAMINE TRANSPORTER; AUTOANTIBODY; PEPTIDE;

ADULT; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; BCG VACCINATION; BLOOD SAMPLING; HIGH CONTENT PEPTIDE MICROARRAY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; LYMPH NODE; MICROARRAY ANALYSIS; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; REVIEW; TUBERCULOUS LYMPHADENITIS; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; CHEMISTRY; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PROCEDURES; TUBERCULOSIS; VACCINATION;

AMINO ACID SEQUENCE; ANTIBODY FORMATION; AUTOANTIBODIES; BCG VACCINE; HUMANS; IMMUNITY, HUMORAL; MYCOBACTERIUM BOVIS; PEPTIDES; PROTEIN ARRAY ANALYSIS; TUBERCULOSIS; VACCINATION;

EID: 85014259491     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.01.027     Document Type: Review

References (53)

1. 1 Luca, S., Mihaescu, T., History of BCG vaccine. Maedica (Buchar), 8, 2013, 6.
2. 2 Roy, A., Eisenhut, M., Harris, R.J., Rodrigues, L.C., Sridhar, S., Habermann, S., et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ, 349, 2014, g4643.
3. 3 Favorov, M., Ali, M., Tursunbayeva, A., Aitmagambetova, I., Kilgore, P., Ismailov, S., Chorba, T., Comparative tuberculosis (TB) prevention effectiveness in children of bacillus Calmette-Guerin (BCG) vaccines from different sources, Kazakhstan. PLoS One, 7, 2012, e32567.
4. 4 Winters, W.D., Lamm, D.L., Antibody responses to bacillus Calmette–Guerin during immunotherapy in bladder cancer patients. Cancer Res 41 (1981), 2672–2676.
5. 5 Soares, A.P., Scriba, T.J., Joseph, S., Harbacheuski, R., Murray, R.A., Gelderbloem, S.J., et al. Bacillus Calmette–Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 180 (2008), 3569–3577.
6. 6 Achkar, J.M., Casadevall, A., Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13 (2013), 250–262.
7. 7 Behr, M.A., Wilson, M.A., Gill, W.P., Salamon, H., Schoolnik, G.K., Rane, S., Small, P.M., Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999), 1520–1523.
8. 8 Vasekar, M., Degraff, D., Joshi, M., Immunotherapy in bladder cancer. Curr Mol Pharmacol 9:3 (2016), 242–251.
9. 9 Faustman, D.L., Wang, L., Okubo, Y., Burger, D., Ban, L., Man, G., et al. Proof-of-concept, randomized, controlled clinical trial of bacillus Calmette–Guerin for treatment of long-term type 1 diabetes. PLoS One, 7, 2012, e41756.
10. 10 Ristori, G., Romano, S., Cannoni, S., Visconti, A., Tinelli, E., Mendozzi, L., et al. Effects of bacille Calmette–Guerin after the first demyelinating event in the CNS. Neurology 82 (2014), 41–48.
11. 11 Kaufmann, S.H., Cotton, M.F., Eisele, B., Gengenbacher, M., Grode, L., Hesseling, A.C., Walzl, G., The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13 (2014), 619–630.
12. 12 World Health Organization, Global tuberculosis report 2015., 2015, WHO, Geneva p. 204.
13. 13 Aguas, A., Esaguy, N., Sunkel, C.E., Silva, M.T., Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DR beta subsets of major histocompatibility complex class II molecules. Infect Immun 58 (1990), 1461–1470.
14. 14 Shapira, Y., Agmon-Levin, N., Shoenfeld, Y., Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 38 (2010), 169–177.
15. 15 Lawrence, D.A., Transforming growth factor-beta: a general review. Eur Cytokine Netw 7 (1996), 363–374.
16. 16 English, K., Ryan, J.M., Tobin, L., Murphy, M.J., Barry, F.P., Mahon, B.P., Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156 (2009), 149–160.
17. 17 Elias, D., Britton, S., Aseffa, A., Engers, H., Akuffo, H., Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine 26 (2008), 3897–3902.
18. 18 Valentini, D., Gaseitsiwe, S., Maeurer, M., Humoral ‘reactome’ profiles using peptide microarray chips. Trends Immunol 31 (2010), 399–400.
19. 19 Gaseitsiwe, S., Valentini, D., Mahdavifar, S., Magalhaes, I., Hoft, D.F., Zerweck, J., et al. Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One, 3, 2008, e3840.
20. 20 Reilly, M., Valentini, D., Visualisation and pre-processing of peptide microarray data. Methods Mol Biol 570 (2009), 373–389.
21. 21 Valentini, D., Ferrara, G., Advani, R., Hallander, H.O., Maeurer, M.J., Serum reactome induced by Bordetella pertussis infection and pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis. BMC Immunol, 16, 2015, 40.
22. 22 Ambati, A., Valentini, D., Montomoli, E., Lapini, G., Biuso, F., Wenschuh, H., et al. H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix((R)) vaccination. Immunology 145 (2015), 357–366.
23. 23 Nahtman, T., Jernberg, A., Mahdavifar, S., Zerweck, J., Schutkowski, M., Maeurer, M., Reilly, M., Validation of peptide epitope microarray experiments and extraction of quality data. J Immunol Methods 328 (2007), 1–13.
24. 24 Tusher, V.G., Tibshirani, R., Chu, G., Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98 (2001), 5116–5121.
25. 25 Phipson, B., Lee, S., Majewski, I.J., Alexander, W.S., Smyth, G.K., Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. Ann Appl Stat 10 (2016), 946–963.
26. 26 Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G., Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99 (2002), 6567–6572.
27. 27 Valentini, D., Rao, M., Ferrara, G., Perkins, M., Dodoo, E., Zumla, A., Maeurer, M., Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. Int J Infect Dis, 2017 Feb 9. pii: S1201-9712(17)30018-8.
28. 28 Brachtel, E.F., Washiyama, M., Johnson, G.D., Tenner-Racz, K., Racz, P., MacLennan, I.C., Differences in the germinal centres of palatine tonsils and lymph nodes. Scand J Immunol 43 (1996), 239–247.
29. 29 Rahman, S., Gudetta, B., Fink, J., Granath, A., Ashenafi, S., Aseffa, A., et al. Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory t cells in the granulomatous lesions. Am J Pathol 174 (2009), 2211–2224.
30. 30 Aaby, P., Kollmann, T.R., Benn, C.S., Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 15 (2014), 895–899.
31. 31 Hanekom, W.A., The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 1062 (2005), 69–78.
32. 32 Askeland, E.J., Newton, M.R., O'Donnell, M.A., Luo, Y., Bladder cancer immunotherapy: BCG and beyond. Adv Urol, 2012, 2012, 181987.
33. 33 Ravn, P., Boesen, H., Pedersen, B.K., Andersen, P., Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette–Guerin. J Immunol 158 (1997), 1949–1955.
34. 34 Elsasser, J., Janssen, M.W., Becker, F., Suttmann, H., Schmitt, K., Sester, U., et al. Antigen-specific CD4T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis. PLoS One, 8, 2013, e69892.
35. 35 Lo, W.L., Donermeyer, D.L., Allen, P.M., A voltage-gated sodium channel is essential for the positive selection of CD4(+) T cells. Nat Immunol 13 (2012), 880–887.
36. 36 Russell, S.M., Johnston, J.A., Noguchi, M., Kawamura, M., Bacon, C.M., Friedmann, M., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266 (1994), 1042–1045.
37. 37 Zhu, X., Marcus, W.D., Xu, W., Lee, H.I., Han, K., Egan, J.O., et al. Novel human interleukin-15 agonists. J Immunol 183 (2009), 3598–3607.
38. 38 Byrd, V.M., Kilkenny, D.M., Dikov, M.M., Reich, M.B., Rocheleau, J.V., Armistead, W.J., et al. Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway. Immunol Cell Biol 81 (2003), 440–450.
39. 39 Edling, C.E., Hallberg, B., c-Kit—a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 39 (2007), 1995–1998.
40. 40 Langley, A.R., Chambers, H., Christov, C.P., Krude, T., Ribonucleoprotein particles containing non-coding Y RNAs, Ro60, La and nucleolin are not required for Y RNA function in DNA replication. PLoS One, 5, 2010, e13673.
41. 41 Franceschini, F., Cavazzana, I., Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38 (2005), 55–63.
42. 42 Goeb, V., Salle, V., Duhaut, P., Jouen, F., Smail, A., Ducroix, J.P., et al. Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol 148 (2007), 281–287.
43. 43 Allen, S.S., Cassone, L., Lasco, T.M., McMurray, D.N., Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs. Infect Immun 72 (2004), 1358–1363.
44. 44 Roberts, T., Beyers, N., Aguirre, A., Walzl, G., Immunosuppression during active tuberculosis is characterized by decreased interferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta, and interleukin-4 mRNA levels. J Infect Dis 195 (2007), 870–878.
45. 45 Eiden, L.E., Schafer, M.K., Weihe, E., Schutz, B., The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 447 (2004), 636–640.
46. 46 Tritsch, N.X., Ding, J.B., Sabatini, B.L., Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 490 (2012), 262–266.
47. 47 Lin, L., Yee, S.W., Kim, R.B., Giacomini, K.M., SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 14 (2015), 543–560.
48. 48 Zhu, Q., Zhang, M., Shi, M., Liu, Y., Zhao, Q., Wang, W., et al. Human B cells have an active phagocytic capability and undergo immune activation upon phagocytosis of Mycobacterium tuberculosis. Immunobiology 221 (2016), 558–567.
49. 49 Rao, M., Valentini, D., Poiret, T., Dodoo, E., Parida, S., Zumla, A., et al. B in TB: B cells as mediators of clinically relevant immune responses in tuberculosis. Clin Infect Dis 61:Suppl 3 (2015), S225–S234.
50. 50 Achkar, J.M., Chan, J., Casadevall, A., B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 264 (2015), 167–181.
51. 51 Axelsson-Robertson, R., Ju, J.H., Kim, H.Y., Zumla, A., Maeurer, M., Mycobacterium tuberculosis-specific and MHC class I-restricted CD8+ T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosis. Int J Infect Dis 32 (2015), 13–22.
52. 52 Zumla, A., Rao, M., Parida, S.K., Keshavjee, S., Cassell, G., Wallis, R., Axelsson-Robertsson, R., Doherty, M., Andersson, J., Maeurer, M., Inflammation and tuberculosis: host-directed therapies. J Intern Med. 277:April (4) (2014), 373–387.
53. 53 Britschgi, M., Olin, C.E., Johns, H.T., Takeda-Uchimura, Y., LeMieux, M.C., Rufibach, K., et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A 106 (2009), 12145–12150.